Sitemap
- Home
- About Us
- Pipeline
- Scientific Background
- Media
- Press Releases
- sterna biologicals successfully completes Phase I development programme of SB010
- W/O/W emulsions effectively protect DNAzymes from degradation and enhance skin penetration
- Experimental data demonstrate that GATA-3-specific DNAzymes do not lead to unspecific immune cell activation
- sterna biologicals completes first-in-man study of SB010
- sterna biologicals commences phase I clinical trial of first-in-class DNAzyme-based GATA-3 antagonist for the treatment of moderate to severe Th2-driven asthma
- Mailing List
- Press Kits & Downloads
- Picture Gallery
- sterna biologicals successfully completes Phase I development programme of SB010
- W/O/W emulsions effectively protect DNAzymes from degradation and enhance skin penetration
- Experimental data demonstrate that GATA-3-specific DNAzymes do not lead to unspecific immune cell activation
- sterna biologicals completes first-in-man study of SB010
- sterna biologicals commences phase I clinical trial of first-in-class DNAzyme-based GATA-3 antagonist for the treatment of moderate to severe Th2-driven asthma
- Press Releases
- Contacts